glp-1 food industry news today What to know about packaged foods aimed at users of weight-loss drugs Food companies are targeting users

May predispose you to catching a cold : Another potential adverse reaction is the common cold , and general stuffiness can make you a mouth breather, which can cause dry mouth

Ferrannini G, Gerstein H, Colhoun HM, et al

Patients receiving Foundayo 17.2 mg lost an average of 19.7 pounds, compared with 11.0 pounds among those receiving oral semaglutide 14 mg, corresponding to a 73.6% greater relative weight reduction. Notably, 37.1% of patients receiving the higher dose of Foundayo achieved an A1C below 5.7%, a threshold generally considered within the normal glycemic range, compared with 12.5% of patients receiving oral semaglutide. "ACHIEVE-3 provides the first head-to-head data on oral GLP-1s in type 2 diabetes, with orforglipron showing greater A1C and weight reductions than oral semaglutide," said Julio Rosenstock, MD, clinical professor of medicine at the University of Texas Southwestern Medical Center and lead investigator for ACHIEVE-3. What did the additional ACHIEVE studies show

In the United States, obesity prevalence among children and adolescents aged 2 to 19 years increased from 17.7% in 20112012 to 21.5% in 20172020, underscoring the accelerating nature of this epidemic

Pi-Sunyer et al